bluuebunny/crossref_metadata_2025_split huggingface dataset:
Monitoring hepatocellular carcinoma by using a monoclonal immunoenzymometric assay for alpha-fetoprotein.
Authors: Kelsten M L , Chan D W , Bruzek D J , Rock R C 
Published: January 2020

Abstract
A monoclonal immunoenzymometric assay for alpha-fetoprotein (M-AFP) was evaluated with respect to its utility in monitoring hepatocellular carcinoma (HCC) patients. Earlier (Clin Chem 1986;32:1318-22), we found this immunoassay to demonstrate abilities similar to polyclonal AFP assays, and we suggested that changes in M-AFP correlated with changes in intrahepatic tumor volume in most HCC patients. In the present study, 107 HCC patients were evaluated between 1978 and 1986. Patient demographics characterized this study population as being similar to those seen in regions with low incidence of HCC. Changes in serum M-AFP concentration correlated moderately (r = 0.55) with changes in intrahepatic tumor volume. The AFP concentration in serum was found to be a statistically significant independent predictor of survival; patients with above-normal M-AFP (AFP[+]) at presentation demonstrated a median survival time of 10 months, compared with 16 months for patients with "normal" values for M-AFP (AFP[-]) (P = 0.008). This prognostic pattern persisted when adjusted for serum bilirubin concentration (AFP[+] 12 months vs AFP[-] 29 months, P = 0.01).
Liquid-chromatographic profiling of solutes in serum of uremic patients undergoing hemodialysis and chronic ambulatory peritoneal dialysis (CAPD); high concentrations of pseudouridine in CAPD patients.
Authors: Schoots A C , Gerlag P G , Mulder A W , Peeters J A , Cramers C A 
Published: January 2020

Abstract
Using "high performance" liquid chromatography, we studied non-protein-bound fractions and total concentrations of 18 solutes accumulating in sera from a group of 12 patients who were undergoing chronic ambulatory peritoneal dialysis (CAPD) and in predialysis sera from a group of 15 hemodialysis (HD) patients. We monitored longitudinal changes in solute concentrations for two patients with respect to change of therapy between HD and CAPD. The concentrations of pseudouridine (P less than 0.001), uric acid (P less than 0.001), and an unknown fluorescent solute, "UKF3" (P less than 0.01), differed in sera of HD and CAPD patients. When standardized with respect to serum creatinine concentrations, the concentration of the transfer-RNA catabolite, pseudouridine, was significantly (P less than 0.0001) higher in sera of CAPD patients than in HD patients, suggesting an increase in turnover of transfer RNA. In stepwise linear discriminant analysis, the combination of pseudouridine and the probably biochemically related fluorescent unknown, UKF3, contributed most to the differentiation between sera from CAPD and HD patients.
Monitoring breast cancer with CA 549.
Authors: Chan D W , Beveridge R A , Bruzek D J , Damron D J , Bray K R , Gaur P K , Ettinger D S , Rock R C 
Published: January 2020

Abstract
CA 549, a new marker for breast cancer, was measured in serum of 719 patients by an immunoradiometric assay involving two monoclonal antibodies: BC4E 549, developed against a breast-tumor cell line, and BC4N 154, developed against milk fat-globule membrane. The reference interval for healthy women was 0-11 kilo-units/L. The percentages of patients with CA 549 greater than 11 kilo-units/L for benign conditions are: 0% pregnancy, 1% breast, 26% liver; and for nonbreast metastatic cancers: 12% endometrial, 33% lung, 40% prostatic, and 50% ovarian. In women with breast cancer who were receiving or had completed adjuvant therapy with no evidence of disease there was an 11% increase in CA 549. For patients with metastatic breast cancer, 19% of those in complete remission, 63% of those in partial remission, and 88% of those with systemic progression had increased CA 549. CA 549 is a more specific marker than carcinoembryonic antigen (CEA) in nonmalignant disease, nonbreast malignancies, and adjuvant breast-cancer patients, and it is more sensitive in breast-cancer patients with progressive disease than is CEA. We could show CA 549 to be superior to CEA for detecting active breast cancer in patients with malignant or nonmalignant breast diseases. In monitoring 19 adjuvant-treated patients, CA 549 correlated more closely with the clinical course than did CEA values and, when increased, predicted a clinical recurrence. In 18 breast-cancer patients with metastasis, monitored for two to three years, the change of CA 549 values paralleled disease courses more often than did CEA values.
Analytical bias for cholesterol and the percent of the population deemed at risk for coronary heart disease.
Authors: Kroll M H , Ruddel M , Elin R J 
Published: January 2020

Abstract
The effect of methodological bias on the population at risk is dependent on the location of the reference value in the distribution of the population. We fitted the cumulative distribution for cholesterol to a rational function and calculated the apparent reference values for four biased methods: Technicon SMAC (2.6%), DuPont aca (4.0 to 4.8%), Kodak DT-60 (-2.0 to -5.5%), and BMD Reflotron (-7.4 to -7.8%). With the true and apparent reference values for cholesterol and the rational function, we determined the percentage increase or decrease in the population deemed at risk for coronary heart disease. The population at risk increased by as much as 48% for methods with positive bias, and decreased by as much as 54% for methods with negative bias. If we restrict the percentage of the population incorrectly diagnosed to 3% and use reference values (cut points) recommended by the National Cholesterol Education Program, the maximum allowable methodological bias would be 1.6% for positive bias and -1.55% for negative bias. Therefore, an absolute methodological bias of 3% (as recommended by the Laboratory Standardization Panel) may be too liberal.
Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases.
Authors: Kropf J , Gressner A M , Negwer A 
Published: January 2020

Abstract
We examined the efficacy of laminin assay in serum for diagnosis of fibrotic liver diseases. Values for subjects with liver disease significantly (P less than 0.05) exceeded those for healthy subjects and patients with nonhepatic diseases. At a cutoff value of 1.45 kilo-units(arb.)/L (approximately 330 micrograms/L) and an assumed prevalence of fibrotic liver diseases of 0.5, positive and negative predictive values of the test were 0.97 and 0.83, respectively, for the comparison with a healthy reference population and 0.81 and 0.80 for nonhepatic diseased patients. Increases in laminin concentration were positively correlated with the extent of fibrotic transition of the liver. Discrimination between fibrotic and cirrhotic stages of chronic liver diseases by means of laminin assay was better than with the amino-terminal propeptide of type III procollagen. According to the criteria of diagnostic efficacy, we conclude that determination of laminin in serum improves the possibilities of clinical-chemical diagnosis of liver fibrosis and cirrhosis. However, as commonly true for other biochemical tests, determination of laminin cannot replace conventional diagnostic methods.
Nonspecificity of a direct 17 alpha-hydroxyprogesterone radioimmunoassay kit when used with samples from neonates.
Authors: Makela S K , Ellis G 
Published: January 2020

Abstract
We analyzed 240 samples for 17 alpha-hydroxyprogesterone (17-OHP) with the direct-assay kit ("Coat-A-Count" method for serum samples) from Diagnostic Products Corp. (DPC). The specimens were from 50 patients with known or suspected congenital adrenal hyperplasia (CAH); 74 mostly hospitalized neonates and infants, ages three days to three months; and 116 other patients, ages six months to 23 years. Samples from the CAH group were also analyzed with our in-house assay. For 39 of the neonatal samples, the analysis with the DPC assay was repeated with re-solubilized material that had been extracted from the serum with organic solvents. Values for "17-OHP" measured with the DPC direct assay were high, not only in CAH patients, but also in many of the unaffected neonates and infants. The extraction properties of the cross-reacting immunoreactive material into various organic solvent systems were different from those of 17-OHP, and were more like those of steroid sulfates. Because of this significant cross-reactivity, we recommend that the DPC kit not be used for sera from children younger than six months of age, unless the method is modified to include an extraction step.
Multicenter evaluation of a specific pancreatic isoamylase assay based on a double monoclonal-antibody technique.
Authors: Tietz N W , Burlina A , Gerhardt W , Junge W , Malfertheiner P , Murai T , Otte M , Stein W , Gerber M , Klein G 
Published: January 2020

Abstract
Eleven evaluators from nine laboratories in five countries evaluated a new immunoinhibition method for pancreatic isoamylase determination that is as simple to perform as that for total amylase. The precision at low and intermediate activity concentrations was superior, and at high concentrations it equalled that of the wheat-germ inhibitor method. The test was linear to approximately 2000 U/L, depending on the instrumentation used. The percentage salivary isoamylase activities remaining in specimens after reaction with two monoclonal antibodies ranged from 2 to 4.4%. Comparative studies showed good correlation with the wheat-germ inhibitor (r greater than 0.978) and electrophoresis methods (r = 0.920). Hemolysis, lipemia, and bilirubinemia have no effect on results. Interlaboratory studies demonstrated excellent transferability of the method, if instruments are calibrated with the same calibrator. Reference intervals for pancreatic isoamylase are 13 to 64 U/L (25 degrees C), 13 to 83 U/L (30 degrees C), and 17 to 115 U/L (37 degrees C). A clinical evaluation of patients with acute pancreatitis showed that pancreatic isoamylase has a greater clinical sensitivity than total amylase.
High-molecular-mass alkaline phosphatase: simplified and highly sensitive determination by liquid chromatography.
Authors: Schoenau E , Boeswald W , Herzog K H , Scheele J , Boehles H J , Stehr K 
Published: January 2020

Abstract
This simplified HPLC method for measurement of high-molecular-mass alkaline phosphatase (high-Mr AP; EC 3.1.3.1) in serum and bile is rapid (time for column preparation and separation 30 min), reproducible (CV 4.2%), and highly sensitive (detects high-Mr AP in healthy controls at 1-3% of total AP activity in serum), and is suitable for processing small batches of sample. We characterized high-Mr AP in serum and bile by incubating samples with L-phenylalanine, neuraminidase, 1-butanol, or wheat-germ lectin, and by determining stability to heat. High-Mr AP activity was determined in sera of patients with various liver diseases (4-32% of total AP serum activity) and results were compared with those by electrophoresis on agarose.
Extremely high values of prostate-specific antigen in patients with adenocarcinoma of the prostate; demonstration of the "hook effect".
Authors: Vaidya H C , Wolf B A , Garrett N , Catalona W J , Clayman R V , Nahm M H 
Published: January 2020

Abstract
We reviewed 721 consecutive samples submitted for measurement of prostate-specific antigen (PSA) over five months. We identified three patients with extremely high PSA concentrations: 650, 1840, and 3280 micrograms/L (their acid phosphatase activities were 3.2, 1337, and 2.8 U/L, respectively), and present case reports for the latter two. Serial dilutions of samples obtained from the patient with the highest PSA concentration indicated that the one-step Tandem-PSA assay gave falsely low values for high concentrations of PSA, an observation consistent with the phenomenon of the "hook effect." This effect was not observed when the sample was reanalyzed for PSA by a two-step procedure.
Abnormalities in thyroid function associated with chronic therapy with methadone.
Authors: English T N , Ruxton D , Eastman C J 
Published: January 2020

Abstract
We studied 145 clinically euthyroid patients on maintenance methadone therapy for narcotic withdrawal, to characterize abnormalities in thyroid-function tests induced by methadone. About a third had increased total thyroxin (T4) and total triiodothyronine (T3) concentrations in serum. The mean concentrations of T3, T4, and thyroxin-binding globulin (TBG) in serum were significantly greater (P less than 0.001 each) in these patients than in a euthyroid control group. There was a corresponding decrease in the T3 uptake (T3U) test, but the free thyroxin index (FTI) failed to correct for the increased TBG concentration in 15.9% of the patients. Individual and mean concentrations of free T3 (FT3) and free T4 (FT4) in serum and results of an "ultrasensitive" test for thyrotropin (TSH-IRMA) were within normal limits and confirmed the euthyroid state. We conclude that prolonged therapy with methadone causes increases in TBG, T3, and T4 in serum. FT3, FT4, and TSH-IRMA estimations are recommended as the diagnostic thyroid tests to use for patients on methadone maintenance therapy.
Use of creatine kinase MB isoenzyme for diagnosing myocardial infarction when total creatine kinase activity is high.
Authors: Thompson W G , Mahr R G , Yohannan W S , Pincus M R 
Published: January 2020

Abstract
The usefulness of measuring creatine kinase MB isoenzyme for diagnosing myocardial infarction when activities of total creatine kinase are very high is unclear. We conducted a retrospective study in an urban hospital that serves a largely indigent population. We concentrated on 146 patients whose creatine kinase activity was greater than 1000 U/L (upper limit of normal: 165 U/L for women and 225 U/L for men), with MB isoenzyme greater than 10 U/L and less than 5% of total creatine kinase. The positive predictive value of MB isoenzyme (isoimmune method) values greater than 10 U/L was between 11.6% and 56.8% when the value for total creatine kinase exceeded 1000 U/L. Using different values (MB greater than 4% of total creatine kinase) as positive for myocardial infarction would have resulted in far fewer false-positives, but 10 cases of myocardial infarction would have been missed. The most appropriate cutoff value for MB isoenzyme in this population (total creatine kinase greater than 1000 U/L) was found to be greater than 2% of total creatine kinase.
Activity of low-density lipoprotein receptors as estimated from concentrations of apolipoprotein B and C-II in serum.
Authors: Ito H , Naito C , Hayashi H , Kawamura M 
Published: January 2020

Abstract
The correlation between low-density lipoprotein (LDL) receptor activity and concentrations of lipids and apolipoproteins in serum was examined in 12 subjects with heterozygous familial hypercholesterolemia (FH) and in four with non-FH type II hyperlipoproteinemia. Concentrations of high-density lipoprotein cholesterol and of apolipoproteins (apo) A-I, C-II, and C-III were significantly positively correlated with LDL receptor activity, whereas LDL receptor activity was significantly inversely correlated with LDL cholesterol and apo B concentrations, and with apo ratios B/A-I and B/A-II. Neither total serum cholesterol, triglyceride, phospholipid, apo A-I, nor apo E concentrations correlated significantly with LDL receptor activity. Multiple regression analysis, with LDL receptor activity as the dependent variable, revealed concentrations of apo B and apo C-II to be the principal determinant factors. To confirm this, we subsequently calculated the LDL receptor activities before and after administration of CS-514, an inhibitor of hydroxymethylglutaryl-CoA reductase (EC 1.1.1.88), which increases the hepatic LDL receptor activity and decreases the concentration of cholesterol in serum. This drug increased calculated LDL receptor activities significantly, with a significant decrease in serum cholesterol.
Novel routine assay of thyroperoxidase autoantibodies.
Authors: Ruf J , Czarnocka B , Ferrand M , Doullais F , Carayon P 
Published: January 2020

Abstract
This radioimmunoassay was developed for specific and large-scale routine measurement of autoantibodies to thyroperoxidase (TPO), an enzyme recently identified as the thyroid microsomal antigen. Because of the scarcity of purified thyroperoxidase, we did not base the assay on the antigen-coated method but rather on autoantibody inhibition of the binding of labeled TPO to a solid-phase-bound monoclonal antibody to TPO. This assay design ensured highly specific measurements without interference from irrelevant thyroid antigens and autoantibodies. When we used affinity-purified autoantibodies to TPO as standards, the range of the curve extended over 10(3)-fold differences in the autoantibodies' concentrations, which allowed us to assay most sera without dilution. Within- and between-assay coefficients of variation (CVs) ranged from 6.1% to 11.5% and from 6.6% to 12.0%, respectively. The correlation between anti-TPO and antimicrosomal autoantibodies, as assessed by hemagglutination test, was highly significant (r = 0.90, P less than 0.0001). This assay is sensitive, easy to perform, and requires only trace amounts of purified TPO.
HPLC measurement of phenylalanine in plasma.
Authors: Atherton N D , Green A 
Published: January 2020

Abstract
Measurement of phenylalanine in plasma is required for the diagnosis and subsequent dietary management of phenylketonuria (PKU). We have developed an isocratic high-performance liquid-chromatographic (HPLC) method, with ultraviolet detection. For this measurement 10 microL of plasma is needed, and the complete analysis can be done in less than 15 min. Interbatch coefficients of variation for human plasma samples (phenylalanine 136-1541 mumol/L) ranged between 2.2% and 4.4%. The method has a wide linear range (10-3500 mumol/L), and results (y) correlated well with those (x) of an ion-exchange chromatographic method (r = 0.996; y = 1.014 x - 11.9; n = 64, range 22-1823 mumol/L). Only standard HPLC equipment is needed and no specialized sample preparation or detection system is required. The procedure has proved robust and reliable in regular routine use.
A longitudinal study of cholinesterase changes in pregnancy.
Authors: Evans R T , O'Callaghan J , Norman A 
Published: January 2020

Abstract
Serum cholinesterase activity was measured at intervals before, during, and after 44 pregnancies in 43 women. Three patterns of change were seen: (a) A decline in activity after conception, with no return towards pre-conception values before delivery (20 pregnancies). (b) A decline in activity accompanied by a partial or complete return to pre-conception values before delivery (19 pregnancies). (c) Either no discernible decline or increased activity during gestation (five pregnancies). We saw no association between these patterns and either the sex of the child, parity, smoking history, or alcohol intake. However, the continuous decrease in cholinesterase activity occurred in the youngest group of women, a decrease followed by an increase in the intermediate age group, and no decrease at all in the oldest group. Although not all the age-related differences quite reached statistical significance, these findings suggest that the patterns of change may be determined by some aspect of maternal physical maturity.
A new method for D-glucaric acid excretion measurement that is suitable for automated instruments.
Authors: Mocarelli P , Brambilla P , Colombo L , Marocchi A , Crespi C , Tramacere P , Mondonico A 
Published: January 2020

Abstract
Urinary excretion of D-glucaric acid (uGA) is an index of type II hepatic microsomal enzyme induction, indirectly revealing possible organic effects of some drugs and environmental pollutants. However, its determination is often cumbersome. We suggest a new, fast microanalytical method for uGA determination in which beta-glucuronidase (BG; EC 3.2.1.31) activity inhibition produced by uGA-derived 1,4-D-glucarolactone is measured. With use of purified BG, the method is suitable for centrifugal analyzers, allowing assay of greater than 100 samples per day. Moreover, the method measures uGA more accurately than other enzymatic methods based on BG inhibition. The within-day CV ranges from 7.9% to 4.6% (uGA 31.55-121.31 mumol/L); the between-day CV ranges from 11.5% to 5.0% (uGA 26.09-124.10 mumol/L). The detection limit is 6.0 mumol/L. The standard curve is linear from 10 to 200 mumol/L. Mean analytical recovery is 100%. Comparison with the method of Simmons et al. (Clin Chim Acta 1974;51:47-51) gave a correlation of r = 0.978, y = 1.40x-2.81. Reference intervals were established in a healthy population sample of 369 people (165 under 14 y), and uGA, expressed in micromoles per gram of creatinine, was higher in women than in girls or in males.
New enzymatic determination of sialic acid in serum.
Authors: Teshima S , Tamai K , Hayashi Y , Emi S 
Published: January 2020

Abstract
This enzymatic method for determination of sialic acid involves use of neuraminidase (EC 3.2.1.18), N-acetylneuraminate lyase (EC 4.1.3.3), acylglucosamine 2-epimerase (EC 5.1.3.8), N-acetylhexosamine oxidase (from Pseudomonas sp.), and peroxidase (EC 1.11.1.7). Because the method does not require pyruvic acid in the assay medium, interference by pyruvic acid in serum can be avoided. This simple, accurate assay is little affected by other substances in serum.
Immunoassay of alpha 1-acid glycoprotein in the Cobas Bio centrifugal analyzer.
Authors: Verme C N , Ludden T M , Harris S C 
Published: January 2020

Abstract
There is an increasing demand for quantification of serum alpha 1-acid glycoprotein (AAG, orosomucoid) in studies evaluating the protein binding of highly bound basic drugs. This paper describes an adaptation of an automated immunoturbidimetric assay for this protein to the Cobas Bio centrifugal analyzer. Replicate analyses of aliquots from six different solutions were used in determining precision. We also analyzed 367 patients' serum samples, in duplicate, to determine the distribution of AAG in hospitalized patients. The intra- and inter-run CVs ranged from 1.3% to 4.4% and from 0.6% to 6.6%, respectively. AAG concentrations in patients' samples ranged from 0.38 to 3.16 g/L. Results by this method correlate well with those by radial immunodiffusion, with no significant amount of bias between the two methods. This immunoturbidimetric procedure is faster and less expensive than currently used radial immunodiffusion techniques, and precision is acceptable.
An assay of uroporphyrinogen decarboxylase in erythrocytes.
Authors: McManus J , Blake D , Ratnaike S 
Published: January 2020

Abstract
Measurement of uroporphyrinogen decarboxylase (UROD; EC 4.1.1.37) activity in erythrocytes is useful in distinguishing between familial porphyria cutanea tarda (PCT), in which UROD activities are low, and acquired PCT, in which UROD activity is normal. In this method for measuring UROD, pentacarboxylic acid porphyrinogen I (PPI) is used as substrate. A sample of the patient's whole blood is incubated with PPI at 37 degrees C for 30 min at pH 6.0. The reaction is stopped by adding trichloroacetic acid/dimethyl sulfoxide containing mesoporphyrin (internal standard). The coproporphyrin so produced is measured directly by high-performance liquid chromatography, with fluorescence detection. Our values by this method for healthy subjects and non-PCT patients ranged from 1.8 to 4.0 U/L. The CV for the assay was 10% at 1.1 U/L and 9% at 2.4 U/L. Twelve of 42 patients with PCT had low erythrocyte UROD activities. In each of six families of patients with low UROD activity we found at least one other family member with a low UROD activity in erythrocytes.